The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals with certain comorbidities may have a poor immune response and require early booster vaccines. We aimed to assess the immune response after two doses of Ch...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Thachanun Porntharukchareon, Wipada Chartisathian, Manassamon Navinpipat, Chayanee Samdaengpan, Kunsuda Cheirsilpa, Aimwipa Lueprasitsakul, Supanat Worawichawong, Viroj Muangsillapasart, Pratya Pumuthaivirat, Bothamai Dechates, Supamas Sirisreetreerux, Taweegrit Siripongboonsitti, Vimonsri Rangsrisaeneepitak, Kerati Jirawattanapalin, Kriangkrai Tawinprai
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-08-01
Subjects:	chadox1 ncov-19 vaccine comorbidity immunogenicity covid-19
Online Access:	http://dx.doi.org/10.1080/21645515.2023.2251850